A Phase II Study of a Pediatric-Inspired Combination Chemotherapy Regimen in Adults with Acute Lymphoblastic Leukemia

Protocol
12-266
Full Title
A Novel "Pediatric-Inspired" Regimen with Reduced Myelosuppressive Drugs for Adults (aged 18-60) with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
Purpose

There is no standard chemotherapy regimen for treating adults with acute lymphoblastic leukemia (ALL), in terms of which drugs to give and how to give them. Children with ALL tend to respond better to chemotherapy than adults with this disease. The purpose of this study is to determine if the chemotherapy drugs used to treat children with ALL can be used safely and effectively in adults with previously untreated ALL.

Patients in this study will receive different anticancer drugs during different phases over several months. All of the drugs are FDA-approved for treating leukemia.

Investigator
Dan Douer, MD -- Leader, Acute Lymphoblastic Leukemia Program
Dan Douer - Physician Profile
Co-Investigators
Martin S. Tallman, MD -- Chief, Leukemia Service
Martin S. Tallman - Physician Profile
Jae Park, MD
Jae Park - Physician Profile
Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a confirmed diagnosis of Ph-negative previously untreated ALL.
  • Patients must be able to be ambulatory for more than half of their normal waking hours.
  • This study is open to patients ages 18 to 60.

For more information about this study and to inquire about eligibility, please contact Dr. Dan Douer at 212-639-2471.

Disease(s)
Leukemia: Acute Lymphoblastic Leukemia
Locations
ClinicalTrials.gov
Related Diseases

Clinical Trials

Clinical trials can offer you access to a new, experimental treatment before it is available to most patients. Joining a clinical trial is also a way to make a valuable contribution toward the fight against cancer.